EUIPO Supports Major Europe-Wide Action Against Counterfeit Medicines
Published 11 March 2026
Matthew Murphy
The fight against counterfeit medicines received a major boost following a coordinated Europe-wide enforcement operation supported by the European Union Intellectual Property Office (EUIPO). Working alongside law-enforcement and health authorities across the region, the initiative targeted criminal networks involved in the production and distribution of falsified pharmaceutical products.
The operation formed part of Operation Shield, an annual initiative coordinated by Europol that focuses on illegal medicines, doping substances and counterfeit health products. It brought together customs authorities, police forces, medicines regulators and anti-doping agencies from numerous European and international jurisdictions. The large-scale collaboration highlights the increasingly global nature of pharmaceutical crime and the need for coordinated enforcement responses.
A Growing Threat to Public Health
Counterfeit medicines present one of the most dangerous forms of intellectual property infringement. Unlike counterfeit consumer goods such as clothing or electronics, falsified pharmaceuticals pose direct risks to human health. Fake medicines may contain incorrect dosages, harmful chemicals or no active ingredients at all, leaving patients without effective treatment and potentially causing serious harm.
Authorities involved in the operation reported seizures of significant quantities of illicit pharmaceutical products. These included counterfeit prescription medicines, illegal hormone treatments, anabolic steroids and unapproved health supplements. Investigators also targeted illicit online pharmacies and websites that distribute unauthorised medical products to consumers across borders.
The growing role of online distribution has made enforcement particularly challenging. Criminal networks frequently exploit social media platforms, messaging services and e-commerce marketplaces to sell counterfeit pharmaceuticals directly to consumers. These channels allow operators to reach a global audience while masking their identities and avoiding traditional regulatory controls.
The Role of Intellectual Property Enforcement
The involvement of the EUIPO underscores the important link between intellectual property protection and public health enforcement. Counterfeit medicines often infringe trademarks and other IP rights belonging to legitimate pharmaceutical manufacturers. As a result, intellectual property enforcement tools play a critical role in identifying and disrupting illicit supply chains.
The European Union Intellectual Property Office provides analytical support, intelligence and coordination tools that assist law-enforcement agencies in tackling IP-related crime. Through initiatives such as its Observatory on Infringements of Intellectual Property Rights, the EUIPO works closely with customs authorities, police and regulators to combat counterfeit goods entering European markets.
In the pharmaceutical sector, this cooperation is particularly important. Legitimate drug manufacturers invest heavily in research, clinical trials and regulatory approval processes. Counterfeit products undermine those investments while simultaneously exposing patients to serious health risks.
Multi-Agency Cooperation
The operation also involved cooperation with health regulators including the European Medicines Agency (EMA), as well as national medicines authorities and anti-doping bodies. Their expertise is critical in identifying falsified pharmaceutical formulations and ensuring seized products are properly analysed.
Law-enforcement authorities carried out inspections, executed search warrants, and launched criminal investigations against individuals and organisations suspected of involvement in the illegal pharmaceutical trade. The operation also targeted logistics networks and online distribution channels used to transport and market counterfeit medicines.
Such cooperation is essential because counterfeit medicine trafficking typically involves complex international supply chains. Production may occur in one country, packaging in another, and online sales directed at consumers across multiple jurisdictions. Only coordinated enforcement actions can effectively disrupt these networks.
Continuing Challenges
Despite ongoing enforcement efforts, the counterfeit pharmaceutical market continues to grow globally. Demand for cheaper medicines, increased online purchasing and supply chain complexity all create opportunities for organised crime groups.
Authorities therefore emphasise the importance of public awareness and caution when purchasing medicines online. Consumers are urged to obtain pharmaceuticals only from authorised pharmacies and trusted healthcare providers.
At the policy level, operations such as those supported by the EUIPO demonstrate the importance of combining intellectual property enforcement with public health regulation and criminal investigation. By working together across borders, European institutions and national authorities aim to protect both consumers and legitimate pharmaceutical innovation.
As counterfeit medicines remain a persistent global threat, continued cooperation between IP offices, law-enforcement agencies and health regulators will be essential to safeguard the integrity of the pharmaceutical market and protect public health.
The operation formed part of Operation Shield, an annual initiative coordinated by Europol that focuses on illegal medicines, doping substances and counterfeit health products. It brought together customs authorities, police forces, medicines regulators and anti-doping agencies from numerous European and international jurisdictions. The large-scale collaboration highlights the increasingly global nature of pharmaceutical crime and the need for coordinated enforcement responses.
A Growing Threat to Public Health
Counterfeit medicines present one of the most dangerous forms of intellectual property infringement. Unlike counterfeit consumer goods such as clothing or electronics, falsified pharmaceuticals pose direct risks to human health. Fake medicines may contain incorrect dosages, harmful chemicals or no active ingredients at all, leaving patients without effective treatment and potentially causing serious harm.
Authorities involved in the operation reported seizures of significant quantities of illicit pharmaceutical products. These included counterfeit prescription medicines, illegal hormone treatments, anabolic steroids and unapproved health supplements. Investigators also targeted illicit online pharmacies and websites that distribute unauthorised medical products to consumers across borders.
The growing role of online distribution has made enforcement particularly challenging. Criminal networks frequently exploit social media platforms, messaging services and e-commerce marketplaces to sell counterfeit pharmaceuticals directly to consumers. These channels allow operators to reach a global audience while masking their identities and avoiding traditional regulatory controls.
The Role of Intellectual Property Enforcement
The involvement of the EUIPO underscores the important link between intellectual property protection and public health enforcement. Counterfeit medicines often infringe trademarks and other IP rights belonging to legitimate pharmaceutical manufacturers. As a result, intellectual property enforcement tools play a critical role in identifying and disrupting illicit supply chains.
The European Union Intellectual Property Office provides analytical support, intelligence and coordination tools that assist law-enforcement agencies in tackling IP-related crime. Through initiatives such as its Observatory on Infringements of Intellectual Property Rights, the EUIPO works closely with customs authorities, police and regulators to combat counterfeit goods entering European markets.
In the pharmaceutical sector, this cooperation is particularly important. Legitimate drug manufacturers invest heavily in research, clinical trials and regulatory approval processes. Counterfeit products undermine those investments while simultaneously exposing patients to serious health risks.
Multi-Agency Cooperation
The operation also involved cooperation with health regulators including the European Medicines Agency (EMA), as well as national medicines authorities and anti-doping bodies. Their expertise is critical in identifying falsified pharmaceutical formulations and ensuring seized products are properly analysed.
Law-enforcement authorities carried out inspections, executed search warrants, and launched criminal investigations against individuals and organisations suspected of involvement in the illegal pharmaceutical trade. The operation also targeted logistics networks and online distribution channels used to transport and market counterfeit medicines.
Such cooperation is essential because counterfeit medicine trafficking typically involves complex international supply chains. Production may occur in one country, packaging in another, and online sales directed at consumers across multiple jurisdictions. Only coordinated enforcement actions can effectively disrupt these networks.
Continuing Challenges
Despite ongoing enforcement efforts, the counterfeit pharmaceutical market continues to grow globally. Demand for cheaper medicines, increased online purchasing and supply chain complexity all create opportunities for organised crime groups.
Authorities therefore emphasise the importance of public awareness and caution when purchasing medicines online. Consumers are urged to obtain pharmaceuticals only from authorised pharmacies and trusted healthcare providers.
At the policy level, operations such as those supported by the EUIPO demonstrate the importance of combining intellectual property enforcement with public health regulation and criminal investigation. By working together across borders, European institutions and national authorities aim to protect both consumers and legitimate pharmaceutical innovation.
As counterfeit medicines remain a persistent global threat, continued cooperation between IP offices, law-enforcement agencies and health regulators will be essential to safeguard the integrity of the pharmaceutical market and protect public health.